Is PBH a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Prestige Consumer Healthcare (PBH) rests on The biggest acquisition in years just closed: Prestige paid about $1,045 million in cash for Breathe Right and an associated group of brands on June 12, 2026, then drew a further $95 million to buy LaCorium Health, whose Dermal Therapy line leads therapeutic skin care in Australia. The bear case rests on clear Eyes supply remains unreliable, and the Pillar5 remediation intended to fix it is a live drag on gross margin rather than a completed project. Analysts covering it publish targets from $51.00 to $75.00 against a $48.00 share price on November 16, 2026, so even the professionals disagree by 36% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

PBH key stats

At $48.00 on November 16, 2026, Prestige Consumer Healthcare (PBH) has a market cap of $2.3B and a P/E of 14.8 on trailing earnings (9.4 on forward earnings). It next reports earnings around February 4, 2027 (estimated).

Market cap
$2.3B
P/E (trailing)
14.8
P/E (forward)
9.4
EPS (trailing 12 months)
$3.24
Price to book
1.2
Beta
0.29
Next earnings
around February 4, 2027 (estimated)

Market cap, P/E and yield are measured at the $48.00 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Prestige Consumer Healthcare (PBH)?

The last two weeks for Prestige Consumer Healthcare, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • PBH closed at $48.00 on November 16, 2026, up 9.9% over the past five trading days (from $43.67).
  • Prestige Consumer Healthcare next reports quarterly results around February 4, 2027 (estimated).
  • On November 5, 2026, Prestige Consumer Healthcare filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 5, 2026, Prestige Consumer Healthcare filed an 8-K with the SEC reporting quarterly results and information shared with investors (Regulation FD) (Item 2.02, Item 7.01). Read the 8-K on sec.gov
  • On November 6, 2026, Canaccord Genuity lowered its target to $70.00 from $72.00 (Buy).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Prestige Consumer Healthcare Inc. owns over-the-counter healthcare brands rather than inventing them. The portfolio spans Monistat and Summer's Eve in women's health, BC and Goody's pain powders, Clear Eyes and TheraTears eye care, Dramamine, Fleet, Chloraseptic, Luden's, DenTek, Compound W, Nix, Debrox and Boudreaux's Butt Paste, plus Gaviscon in Canada and Hydralyte and the newly acquired Dermal Therapy line in Australia. Most manufacturing is outsourced, so spending goes to advertising and shelf presence instead of factories. Two segments carry the results: North American OTC Healthcare produced about $226 million of the June 2026 quarter's roughly $266 million, and International OTC Healthcare the remaining $40 million. Concentration is real on both ends, with the top five brands at about 39 percent of gross revenue, Walmart at roughly 19 percent and Amazon at roughly 16 percent. The fiscal year ends in March, so the quarter reported on August 6, 2026 was the first of fiscal 2027. The financial shape is a steady cash generator carrying debt raised to buy brands. Fiscal 2026 revenue fell to about $1,088.7 million from about $1,137.8 million as Clear Eyes supply problems bit, and the shares dropped sharply on the May 13, 2026 report. June brought the largest deal in years: about $1,045 million in cash for Breathe Right and related brands, funded with a new seven-year term loan, followed by LaCorium Health in Australia on a further $95 million draw. Net debt moved from roughly $0.93 billion at the March year end to about $2.0 billion by June 30, 2026, close to the company's own equity market value. Management raised fiscal 2027 guidance to roughly $1,290 million to $1,315 million of revenue and $270 million or more of adjusted free cash flow, and paused open-market buybacks to repay borrowings instead. As of October 16, 2026 the shares closed at about $50.08, down roughly 18 percent year to date and about 19 percent over the past year, though up about 11 percent in the past month as the market weighed the new guidance. Fiscal second-quarter results, the first full quarter to include Breathe Right, are scheduled for November 5, 2026.

The bull case: what would have to be true for $75.00

The most optimistic published target on PBH is $75.00, +56.3% from the $48.00 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. The biggest acquisition in years just closed

Prestige paid about $1,045 million in cash for Breathe Right and an associated group of brands on June 12, 2026, then drew a further $95 million to buy LaCorium Health, whose Dermal Therapy line leads therapeutic skin care in Australia. Management says the two add close to 20 percent to the revenue base and raised fiscal 2027 revenue guidance to roughly $1,290 million to $1,315 million entirely on that account. Whether the acquisition model still works comes down to how these brands grow once Prestige's marketing and distribution are applied.

2. Organic growth returned, reported gross margin did not

First-quarter fiscal 2027 revenue of about $265.7 million grew 3.2 percent excluding currency and the acquisition, led by the gastrointestinal and dermatological categories, which is better than the organic decline of fiscal 2026. Reported gross margin fell to roughly 51 percent from about 56 percent a year earlier, weighed down by acquired inventory step-up accounting and the cost of upgrading the Pillar5 plant. GAAP diluted EPS of $0.61 sat well below the adjusted $0.98, so the gap between the two numbers is worth watching over the next few quarters.

3. Free cash flow against a doubled debt load

Adjusted free cash flow was about $83.7 million in the quarter, a record for a first quarter, and the full-year target is $270 million or more. Against that sits roughly $2.0 billion of net debt (about $2.07 billion of total debt and about $89 million of cash), up from about $0.93 billion at the March year end. A July 15, 2026 issue of $400 million in 6.25 percent notes due 2034 replaced paper maturing in fiscal 2028 and pushed the nearest maturity out to 2031, and open-market buybacks stopped, with about $92.2 million still authorized and unused.

4. Clear Eyes supply and the Pillar5 answer to it

Clear Eyes shortages have been the single largest drag on results, and in December 2025 Prestige bought Pillar5 Pharma, an Ontario sterile ophthalmic manufacturer that was already one of its Clear Eyes suppliers, to bring that supply in-house. The plant is being upgraded for long-term capacity, and those costs run through cost of sales today. Management still describes Clear Eyes supply as volatile in its August 2026 commentary, so the recovery is a work in progress rather than a finished one.

The bear case: what would have to be true for $51.00

The most pessimistic published target is $51.00, +6.3% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Prestige Consumer Healthcare is worth if the risks below bite instead of the drivers above.

Clear Eyes supply remains unreliable, and the Pillar5 remediation intended to fix it is a live drag on gross margin rather than a completed project. Net debt of roughly $2.0 billion now sits close to the entire equity market value, and first-quarter interest expense of about $13.9 million reflected only a few weeks of the new term loan, so the run-rate cost of that debt is materially higher from here. Customer concentration cuts both ways: Walmart was roughly 19 percent of gross revenue last quarter and Amazon roughly 16 percent, and Amazon also sells competing house-brand versions of several categories Prestige plays in. Private label and store brands, supplied at scale by Perrigo and sold as Equate, Up and Up and Amazon Basic Care, price against Prestige's brands directly whenever household budgets tighten. Several plaintiff law firms announced investigations after the May 13, 2026 fiscal 2026 results, though as of the Form 10-Q filed August 6, 2026 no securities class action with a case number had been filed and the company disclosed only routine legal matters. The stock has fallen about 18 percent in 2026 and trades well below the mean target of the five analysts who cover it (about $67.80), a gap that reflects doubt about how quickly the debt comes down.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding PBH already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on PBH

5 analysts cover PBH, with an average target of $66.20 (+37.9% against $48.00) and a split of 5 buy, 2 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the PBH forecast and price target page.

How is PBH valued?

Market cap, P/E and dividend yield at today's price are in the PBH key stats above. The business figures below come from Prestige Consumer Healthcare's reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$1.10B, through the quarter ended June 30, 2026
  • Latest quarter (Q1 FY2027): ~$265.7M revenue, up ~6.5%, with ~3.2% organic growth
  • Margins and net income (TTM): Gross ~55%, operating ~21%; net income ~$172M
  • Fiscal 2027 company outlook: ~$1,290M to ~$1,315M revenue, ~$4.55 to ~$4.65 adjusted EPS, ~$270M or more adjusted free cash flow
  • Balance sheet: ~$2.07B debt vs ~$89M cash; no dividend

As of October 2026: Fiscal 2026, which ended March 31, 2026, brought revenue of about $1,088.7 million against about $1,137.8 million the year before, so the trailing figure reflects a down year already in the base. At about 14 times trailing and 10 times forward earnings as of October 16, 2026, the stock looks undemanding next to consumer staples generally, and the reason is visible on the balance sheet: enterprise value including roughly $2.0 billion of net debt is a very different number from the roughly $2.37 billion equity value. Guidance for fiscal 2027 is not comparable to fiscal 2026 without adjustment, because it folds in two acquisitions that closed in June and July 2026; analysts expect the November 5 report to show about $329 million of revenue and $1.07 of adjusted EPS.

How do you decide if PBH is a buy?

Whether PBH is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold PBH indirectly through an index or sector ETF before adding more.

What would change your mind on PBH

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: The biggest acquisition in years just closed stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: clear Eyes supply remains unreliable, and the Pillar5 remediation intended to fix it is a live drag on gross margin rather than a completed project fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the PBH stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about PBH against your real portfolio and see your actual exposure before deciding.

Your questions about Prestige Consumer Healthcare

Ask Walnut's AI anything about PBH and see how it fits what you own.

FAQ

Is PBH a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on The biggest acquisition in years just closed, with revenue (ttm) at ~$1.10B, through the quarter ended June 30, 2026. The bear case rests on clear Eyes supply remains unreliable, and the Pillar5 remediation intended to fix it is a live drag on gross margin rather than a completed project. Analysts covering it are spread from $51.00 to $75.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell PBH?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Clear Eyes supply remains unreliable, and the Pillar5 remediation intended to fix it is a live drag on gross margin rather than a completed project. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $51.00, +6.3% from the $48.00 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for PBH?

+

The biggest acquisition in years just closed. Prestige paid about $1,045 million in cash for Breathe Right and an associated group of brands on June 12, 2026, then drew a further $95 million to buy LaCorium Health, whose Dermal Therapy line leads therapeutic skin care in Australia. The most optimistic analyst target on PBH is $75.00, +56.3% from the $48.00 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for PBH?

+

Clear Eyes supply remains unreliable, and the Pillar5 remediation intended to fix it is a live drag on gross margin rather than a completed project. Net debt of roughly $2.0 billion now sits close to the entire equity market value, and first-quarter interest expense of about $13.9 million reflected only a few weeks of the new term loan, so the run-rate cost of that debt is materially higher from here. Customer concentration cuts both ways: Walmart was roughly 19 percent of gross revenue last quarter and Amazon roughly 16 percent, and Amazon also sells competing house-brand versions of several categories Prestige plays in. Private label and store brands, supplied at scale by Perrigo and sold as Equate, Up and Up and Amazon Basic Care, price against Prestige's brands directly whenever household budgets tighten. Several plaintiff law firms announced investigations after the May 13, 2026 fiscal 2026 results, though as of the Form 10-Q filed August 6, 2026 no securities class action with a case number had been filed and the company disclosed only routine legal matters. The stock has fallen about 18 percent in 2026 and trades well below the mean target of the five analysts who cover it (about $67.80), a gap that reflects doubt about how quickly the debt comes down. The most pessimistic published target is $51.00, +6.3% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does Prestige Consumer Healthcare do?

+

Prestige Consumer Healthcare buys mature over-the-counter brands and runs them for cash, including Monistat, Summer's Eve, BC, Goody's, Clear Eyes and Dramamine.

What would have to change for PBH to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The biggest acquisition in years just closed) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (clear Eyes supply remains unreliable, and the Pillar5 remediation intended to fix it is a live drag on gross margin rather than a completed project) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Prestige Consumer Healthcare do?

+

It markets, sells and distributes over-the-counter healthcare products, mostly brands it acquired rather than developed. Familiar names include Monistat, Summer's Eve, BC and Goody's, Clear Eyes, TheraTears, Dramamine, Fleet, DenTek, Chloraseptic, Compound W and Boudreaux's Butt Paste, plus Breathe Right nasal strips added in June 2026 and Hydralyte and Dermal Therapy in Australia. Most manufacturing is outsourced to third parties.

How does Prestige Consumer Healthcare make money?

+

It sells branded products to mass merchandisers, drug, food, dollar, convenience and club stores and through e-commerce, then supports those brands with advertising instead of research pipelines. Gross margin has historically run in the mid-50s, and because manufacturing is largely outsourced, capital spending is light and most operating profit converts to free cash flow. Advertising and marketing ran about $34.7 million in the June 2026 quarter.

Walnut is informational, not investment advice, and gives no verdict on PBH. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks